Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

Merck Launches First Software for Complete Data Traceability in Microbial QC

publication date: Jun 5, 2024
 | 
author/source: Merck

merck-launches-first-software-complete-data 

M-Trace® Electronic Test Record Software offers digital cleanroom-friendly solution for sterility testing

 

  • M-Trace® Electronic Test Record Software offers digital cleanroom-friendly solution for sterility testing
  • Digitizes pharmaceutical microbial quality control workflows
  • Enables complete, real-time, comprehensive data traceability and regulatory compliance, reducing deviations and human error

 

Merck, a leading science and technology company, has launched its M-Trace® Software & Mobile App, a comprehensive data tracking solution to digitize sterility testing. The software increases overall process safety by automatically documenting data for every step of the testing process. This reduces the likelihood of deviation, false positive results, and the possibility of human error.

“Microbiological quality control labs are critical to ensuring the safety of sterile medicine. Here, the consequences of noncompliance can be very serious,” said Jean-Charles Wirth, Head of Science & Lab Solutions for the Life Science business of Merck. “Our job is to offer the solution that ensures drugs are safe and brought to market to the patients who need them the most -- so data traceability is essential. Digital innovations like M-Trace® bring us one step closer to making the ‘Lab of the Future’ a reality.”

Sterility Testing is the last step of the quality control workflow used by the pharmaceutical industry. It ensures that products such as vaccines, ophthalmic solutions, chemotherapies, and other injectables are 100% free of contaminants. Microbial contamination can expose patients to pathogens/toxins that cause serious metabolic harm or lead to death. Another possible effect is drug degradation resulting in reduced potency. M-Trace® allows drug manufacturers to mitigate safety concerns by notifying of any errors spotted during the process. Furthermore, it provides a complete digital solution for documentation compliance. M-Trace® generates comprehensive reports that enhance data analytics to track trends and ease investigations into out-of-specification results.

Merck is invested in enabling the “Lab of the Future” through innovative workflows to revolutionize scientific research and development. To extract insights from vast amounts of data, solutions are becoming more automated, more autonomous and more continuous. Some of these technologies include AI-powered software pieces focused on digital chemistry and drug discovery, like AIDDISON™ AI powered drug discovery software and SYNTHIA™ Retrosynthesis Software. Other tools digitize processes that have always been manual, like the Digital Reference Materials ChemisTwin™ platform or cell counting systems like MilliCell® DCI and Scepter™ 3.0. With the addition of M-Trace®, Merck continues to support scientists at all stages with solutions that can increase efficiency, safety and success rates of delivering new, safer therapies for patients.

 

 

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck generated sales of € 21 billion in 65 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

 

Recent news from Merck

 

 


If you have not logged into the website then please enter your details below.



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events